SDRL, APA among premarket gainers

Intra-Cellular Therapies (NASDAQ:ITCI) +89% after Caplyta approved by FDA.

Cincinnati Bell (NYSE:CBB) +32% on being acquired by Brookfield Infrastructure

Seadrill (NYSE:SDRL) +27%.

YayYo (NASDAQ:YAYO) +21% after Q3 results.

Soleno Therapeutics (NASDAQ:SLNO) +20%.

DPW Holdings (NYSEMKT:DPW) +19% as CEO stocks up on stock.

Microbot Medical (NASDAQ:MBOT) +19% on launching fully disposable robotic system for endovascular procedures.

Cassava Sciences (NASDAQ:SAVA) +18%.

Progenics Pharmaceuticals (NASDAQ:PGNX) +11% on positive PyL data in prostate cancer.

Diamond Eagle Acquisition (NASDAQ:DEACU) +10% on entering into business combination agreement.

Sarepta Therapeutics (NASDAQ:SRPT) +9% on SRP-9001 deal with Roche outside U.S.

Zosano Pharma (NASDAQ:ZSAN) +7% on NDA submission for Qtrypta.

Proteostasis Therapeutics (NASDAQ:PTI) +7%.

Akari Therapeutics, Plc (NASDAQ:AKTX) +7% on initiating late-stage nomacopan trail in pediatric HSCT-TMA.

NewLink Genetics (NASDAQ:NLNK) +6%.

Apache (NYSE:APA) +6% as Total to pay $100M bonus for Suriname deal.

Abeona Therapeutics (NASDAQ:ABEO) +6%.

Agile Therapeutics (NASDAQ:AGRX) +5%.

Stealth BioTherapeutics (NASDAQ:MITO) +5%.